Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of “Reduce” from Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received a consensus recommendation of “Reduce” from the six research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $12.75.

A number of research analysts recently commented on the company. Truist Financial decreased their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Citigroup upped their price objective on shares of Integra LifeSciences from $9.00 to $11.00 and gave the stock a “sell” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Finally, Argus restated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its holdings in shares of Integra LifeSciences by 58.4% in the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after purchasing an additional 2,710,262 shares in the last quarter. Paradigm Capital Management Inc. NY raised its holdings in shares of Integra LifeSciences by 50.6% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after buying an additional 1,347,700 shares in the last quarter. Invenomic Capital Management LP lifted its position in shares of Integra LifeSciences by 78.3% during the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after buying an additional 463,729 shares during the last quarter. Kotler Kevin bought a new stake in shares of Integra LifeSciences during the 4th quarter worth $5,309,000. Finally, SG Americas Securities LLC acquired a new stake in Integra LifeSciences in the fourth quarter valued at about $4,722,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Trading Down 2.8%

Shares of IART stock opened at $14.10 on Friday. The stock has a market cap of $1.10 billion, a P/E ratio of -2.18 and a beta of 1.08. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $16.49. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The stock has a 50 day simple moving average of $10.59 and a 200 day simple moving average of $11.67.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, research analysts predict that Integra LifeSciences will post 2.44 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.